Cue Biopharma is a company that makes medicines. They told people that they made a loss of money in the second part of this year, but people thought they would lose more money than they actually did. Also, Cue Biopharma made more money than people thought they would make. This might be good news for the people who own the company's stocks. Now, people are waiting to see if the company will continue to make good money or if the stock prices will go down. Read from source...

"Cue Biopharma, Inc. Reports Q2 Loss, Tops Revenue Estimates", titled "Cue Biopharma, Inc. Reports Q2 Loss, Tops Revenue Estimates" are not visible in the article. However, the article presents a mixed picture of Cue Biopharma, Inc., reporting a loss of $0.20 per share for the second quarter of 2024, as compared to the Zacks Consensus Estimate of a loss of $0.29. The company topped revenue estimates for the quarter ended June 2024 by 137.96%, posting revenues of $2.66 million, as compared to year-ago revenues of $1.38 million. Cue Biopharma's shares have lost about 76% since the beginning of the year. The article ends by discussing the outlook for the industry and how it could impact the performance of the stock.

Negative. The article is about Cue Biopharma's Q2 loss, where the company underperformed the market this year. The article mentions that Cue Biopharma shares have lost about 76% since the beginning of the year versus the S&P 500's gain of 13.9%.

1. Cue Biopharma Inc (CUE) reported a Q2 loss of $0.20/share vs Zacks Consensus Estimate of a loss of $0.29/share. However, the company surpassed consensus revenue estimates by 137.96%, posting revenues of $2.66 million. Cue Biopharma, which belongs to the Zacks Medical - Biomedical and Genetics industry, has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Currently, the company has a Zacks Rank #2 (Buy), indicating that shares are expected to outperform the market in the near future. However, investors should monitor management's commentary on the earnings call for further insights into future growth prospects.

Risks:
- The medical industry is highly regulated, and any changes in regulatory policies may adversely affect Cue Biopharma's business operations.
- Cue Biopharma's success heavily relies on the development and approval of its drugs. Any delays or setbacks in the development or approval process may impact the company's revenue and profitability.

2. Sol-Gel Technologies Ltd (SLGL) is expected to report quarterly loss of $0.20/share in its upcoming report, which represents a year-over-year change of +9.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. The company's revenues are expected to be $1.06 million, up 78.8% from the year-ago quarter. However, investors should exercise caution as the company is yet to report its Q2 results, and there is always a risk of the actual figures differing from expectations.

Risks:
- The pharmaceutical industry is highly competitive, with many players developing and marketing similar products. This competition may impact Sol-Gel Technologies' market share and profitability.
- Sol-Gel Technologies' business operations are subject to changes in regulatory policies and any changes that may negatively affect the company's operations need to be closely monitored.

Note: These recommendations are based on the information provided in the article and do not take into account other market or economic factors.